Risk Factors for Recurrent Thrombosis in Patients with Antiphospholipid Syndrome-A Single-Centre Cohort Study [0.03%]
抗磷脂综合征患者反复血栓形成的危险因素-单中心队列研究
Natali Karandyszowska,Francesca Faustini,Hevgin Alagündüz et al.
Natali Karandyszowska et al.
Background: Recurrent thrombosis poses a clinical challenge in patients with antiphospholipid syndrome (APS). There are limited data on risk factors due to its rarity. ...
Venous Thromboembolism Therapy with Edoxaban in Daily Care Patients: Results from the DRESDEN NOAC REGISTRY [0.03%]
新型口服抗凝药在门诊静脉血栓治疗中的应用：来自DRESDEN NOAC登记研究的患者数据
Luise Tittl,Christina Köhler,Sandra Marten et al.
Luise Tittl et al.
Direct oral anticoagulants such as edoxaban are standard of care in current treatment of venous thromboembolism (VTE). However, phase III trial data need confirmation in real-world settings. We extracted data from the prospective, noninterv...
Corrigendum: Management of Cancer-Associated Thrombosis: Unmet Needs and Future Perspectives [0.03%]
癌症相关血栓的管理：未满足的需求和未来展望（勘误）
Anna Falanga,Grégoire Le Gal,Marc Carrier et al.
Anna Falanga et al.
[This corrects the article DOI: 10.1055/s-0041-1736037.]. The Author(s). This is an open access article published by Thieme under the terms of the Creati...
von Willebrand Factor (VWF) Inhibitors in Two Brothers with von Willebrand Disease: A Case Report [0.03%]
两个患血管性血友病兄弟的抑制物产生现象：一例报告
Claudia Djambas Khayat,Anna Pavlova,Sylvia Werner et al.
Claudia Djambas Khayat et al.
The development of inhibitors to von Willebrand factor (VWF) is a rare but potentially serious complication of VWF replacement therapy in patients with von Willebrand disease (VWD). Patients who develop VWF inhibitors may become unresponsiv...
Patient's Awareness of Cancer-Associated Thrombosis: A Canadian Nationwide Survey [0.03%]
加拿大全国癌症相关血栓患者意识调查
Ana C Pizzarossa,Andrea Penaloza,Kristina Vrotniakaite-Bajerciene et al.
Ana C Pizzarossa et al.
Background: Approximately 20% of patients with cancer will have cancer-associated venous thromboembolism (CAT), which is associated with significant morbidity and mortality. Despite its clinical importance, CAT awareness ...
Prospective, Observational Study of the Clinical Outcomes of FVIII Treatment in Adults and Adolescents with Severe Haemophilia A [0.03%]
一项有关八因子治疗成人及青少年重症甲型血友病的临床疗效的前瞻性观察研究
Pratima Chowdary,Liane Khoo,Michael Wang et al.
Pratima Chowdary et al.
Objective: To assess real-world treatment patterns and outcomes in previously treated patients ≥12 years old with severe haemophilia A treated with marketed factor VIII (FVIII) replacement products. ...
In-Hospital Mortality and Hemorrhagic Risks in Traumatic Brain Injury Patients with Early vs. Late Venous Thromboembolism [0.03%]
早期与晚期静脉血栓栓塞的颅脑损伤患者的出血风险及病死率meta分析
Sophie Samuel,Jalon Barnes,Lynn Yamane et al.
Sophie Samuel et al.
Objective: This study reviewed the management and outcomes of traumatic brain injury (TBI) patients who developed venous thromboembolism (VTE) during hospitalization, focusing on the timing of VTE diagnosis and anticoagul...
HSP47 at the Crossroads of Thrombosis and Collagen Dynamics: Unlocking Therapeutic Horizons and Debates [0.03%]
HSP47在血栓和胶原动力学的交汇点：解锁治疗前景与争议
David M Smadja,Alberto F Chocron,M Marc Abreu
David M Smadja
Heat shock protein 47 (HSP47), a collagen-specific molecular chaperone encoded by the SERPINH1 gene, has emerged as a groundbreaking focus in thrombosis research. Recent findings published in "Science" have revolutionized our understanding ...
First Experiences of Patients and Healthcare Professionals with Routine Use of Patient-Reported Outcome Measures for Venous Thromboembolism [0.03%]
静脉血栓栓塞症患者报告结果测量的常规使用情况及其对患者和医护人员的影响体验首次研究
Cindy M M de Jong,Sophie N M Ter Haar,Willem Jan W Bos et al.
Cindy M M de Jong et al.
Background: Venous thromboembolism (VTE) can considerably limit patients' functioning and quality of life. Using patient-reported outcome measures (PROMs), the full impact of VTE on individual patients can be captured. ...
Compassionate Use of Osocimab in Preventing Thrombotic Complications Without Incremental Bleeding: A Case Report [0.03%]
Osocimab同情性使用预防血栓并发症而不增加出血的个案报告
Jan Beyer-Westendorf,Katrin Weber,Falk Eckart et al.
Jan Beyer-Westendorf et al.
Objective: To describe an innovative anticoagulation strategy in a 20-year-old woman with innate jejunal atresia and ultrashort bowel syndrome who was dependent on long-term parenteral nutrition and suffered from multiple...